The OPTIENOX-PCI is a randomized study, which is designed to assess the anticoagulation profile of different dose regimens of enoxaparin, i.e., 0.5 mg/kg, 0.75 mg/kg, and 0.5 mg/kg with additional 0.25 mg/kg, in about 120 patients who plan to undergo elective trans-radial coronary angiography with or without subsequent PCI.